Drug Designing: Open Access is a peer-reviewed and open access journal with an aim to provide rapid and reliable source of information in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide.

Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival. The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer. Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis. A series of small-molecule drugs have been approved for the current cancer therapy. However, their complicated inherent mechanisms may lead to the resistance to such small molecules. Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems. In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chemistry strategies and computational approaches. Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics.

We publish the article related to the effects of dual diagnosis, Treatment, outcomes of the treatment. We invite different types of science communications including original research article, systematic reviews, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

Manuscripts can be published through the online link. Or to the given below Email Id.

With Regards,
Sherry Peterson 
Drug Designing: Open Access
Editorial Manager
Email: drugdesign@longdom.org
Whats App:+1-947-333-4405